• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Australia·Healthcare·MVP.AX
Share

Medical Developments International Limited Stocks

A$ 0.44Last Updated 13.11.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

A$ 30.95M

A$ 0.44
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Favourable analyst view

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Medical Developments International Limited (MDIL) specializes in the development and provision of essential emergency medical solutions, serving global markets including Australia, Europe, and the United States. The company's operations are divided into two primary segments: Pain Management and Respiratory care. Among its key offerings is Penthrox, a product specifically formulated for rapid pain relief in acute trauma and emergency situations. Within the respiratory segment, MDIL supplies equipment designed to assist individuals with conditions like asthma and chronic obstructive pulmonary disease (COPD). Additionally, its comprehensive portfolio features a diverse array of medical devices, encompassing items such as CPR face shields and masks, finger pulse oximeters, flow meter regulators, MDI tourniquets, manually triggered ventilators, oxygen resuscitation kits, and various oxygen therapy and resuscitation apparatus. Established in 2003, the company maintains its headquarters in Scoresby, Australia.

Company Valuation

Fairly valued
4/7

Based on key historical and expected multiples, the stock is fairly valued relative to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBITD

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of MVP.AX is 1.96 and suggests 356% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.11.2026 03:32

SpaceX has successfully caught Starship with its capture tower for the first time. What does this mean for the stock?

14.11.2026 17:01

What's New in Small-Cap Stocks: The Forbes Ranking, Oklo's Plans for Meta, and Ceco's Record

14.11.2026 13:01

Is There Life After Huang? The Rise of Anthropic, and the AI Rally in the Clouds

14.11.2026 04:56

Key Starship tests did not go as planned. SpaceX shares fell

14.11.2026 04:35

The S&P 500 posted its best week in six months. Barclays expects growth for the first time since March

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026